December 21, 2009

Containing Cost Despite the Cost

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

From the University of North Carolina at Chapel Hill, Chapel Hill, NC. Reprints: Joel Farley, PhD, The University of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, 2204 Kerr Hall, Campus Box 7573, Chapel Hill, NC 27599-7573. E-mail: email protected.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Joel F. Farley (Mon,) studied this question.

synapsesocial.com/papers/6a58b0337beebbcfc180897e https://doi.org/https://doi.org/10.1097/mlr.0b013e3181caad9a

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia1994 · 488 citations
2A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls2005 · 531 citations
3Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia2005 · 5,913 citations
4Pathogenesis of atherogenic dyslipidemia2000 · 4 citations
5Managing Psychotropic Drug Costs: Will Formularies Work?2003 · 63 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo